Phase 2 N=40 Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Macular Edema · Retinal Vein Occlusion
Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections
Phase 3 N=357 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Macular Edema · Central Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters
N/A N=30 Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion
Central Retinal Vein Occlusion With Macular Edema
Primary: Visual Acuity — 0.32; 0.44 logMAR units
Phase 2 N=16 Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
Central Retinal Vein Occlusion
Primary: Incidence and Severity of Ocular and Systemic Adverse Events — 1; 0; 0; 1 participants
N/A N=30 A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
Central Retinal Vein Occlusion
Primary: Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts — 12.5; 14; 13.5 letters read correctly
Phase 2 N=12 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Macular Edema · Branch Retinal Vein Occlusion
Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart
Phase 3 N=189 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Macular Edema Secondary to Central Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score — 64; 9 percentage of participants — p=< 0.0001
Phase 3 N=252 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Central Retinal Vein Occlusion
Primary: Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3 — 11.3; -2.7 Letters — p=<0.001
Phase 3 N=177 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants…
Phase 2 N=6 Minocycline to Treat Central Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: The Primary Outcome is the Comparison Between the Minocycline and Placebo Groups of the Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months…
Phase 3 N=68 Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
Non-Ischemic Central Retinal Vein Occlusion
Primary: The Primary Efficacy Endpoint is the Total Number of PRN Bevacizumab Intravitreal Injections Through 24 Weeks — 5; 19; 13; 11 Participants — p=0.00002
Phase 4 N=162 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Central Retinal Vein Occlusion
Primary: The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to…
Phase 3 N=682 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
Macular Edema, Cystoid · Retinal Vein Occlusion
Primary: The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit — 5…
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 4 N=202 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
Macular Edema
Primary: Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15 — 17.5; 19.7; 18.7; 21.0 Letters — p=0.5091
Phase 3 N=392 A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
Macular Edema · Retinal Vein Occlusion
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months — 49.2; 47.4; 48.1; 0.8 Units on a scale — p=<0.0001
Phase 3 N=283 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Macular Edema Secondary to Branch Retinal Vein Occlusion
Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6 — 12.5; 5.0 Letters — p=<0.001
Phase 3 N=362 Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Central Retinal Vein Occlusion
Primary: Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 — 18.9; 18.6 letters read
Phase 3 N=40 Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
Retinal Vein Occlusion
Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants
Phase 2 N=9 Minocycline to Treat Branch Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months Compared to Baseline. — 5.3; 13.0 ETDRS letters
N/A N=323 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
Retinal Vein Occlusion · Macular Edema
Primary: Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence…
N/A N=375 Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 47.56; 5.09 Letters
Phase 4 N=20 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters
Phase 3 N=66 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: Incidence of Serious Adverse Events. — 17 number of serious adverse events
Phase 4 N=30 Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion
Retinal Vein Occlusions
Primary: Change From Baseline Visual Acuity at 6 Months — 2.3; 0.1 ETDRS score
N/A N=608 An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
Macular Edema · Retinal Vein Occlusion
Primary: Number of Participants With Ocular Adverse Events in the Study Eye — 51; 64; 63; 60 participants
Phase 3 N=455 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO) — 59.5; 56.6…
N/A N=27 Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
Macular Edema · Central Retinal Vein Occlusion
Primary: The Change in Visual Acuity (Number of ETDRS Early Treatment Diabetic Retinopathy Study Letters), at Month 6 as Compared With Baseline in Each Treatment Arm — 11.1; 16.1…
Phase 3 N=63 To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions
Retinal Vein Occlusion
Primary: Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart…